R&D

We are active in R&Ds, because we see ourselves more than a producer.

CNBG now has more than 200 on-going research programs, including many national science and technology programs and  several national science and technology supporting projects e.g. “Hand-foot and mouth disease (EV71 virus) vaccine development”.

￭ We established the corporate R&D Center of Excellence in 2003, our strategy is “Science-driven Development”. We focus our research on several “platform technologies”
○ Industrial scale cell culture and fermentation
○ Polysaccharide-Protein conjugate
○ Gene-recombinant technologies
○ Combination vaccines
○ Novel adjuvants
○ Purification technologies

￭ In recent years, our investment in R&D increases at a rate of 40% per year.
￭ In our company, over 700 scientists are working hard to discover and develop new approaches for diseases prevention and treatment.

Academician, Chinese Academy of Engineering      1
Member of Chinese Pharmacopoeia Commission     14
New Drug Evaluation Expert                        over 70
Committee Member of Natural Science Foundation    over 10
Specialists enjoy government allowance              170

￭ Till 2009, we completed 45 national key research projects.
￭ From 1990 to 2009, 30 of our products were awarded as “ National Key New Product”.
￭ 5 of our institutes are authorized to grant Master’s degrees, and 1 institute offer PhD program. In addition, we have 3 postdoctoral centers.
￭ Our pipeline contains several late-stage development vaccine candidates, including a live vector-based anti-HIV vaccine, a hepatitis B vaccine for therapeutic use, a shigella conjugate vaccine and a trivalent rotavirus vaccine. Other vaccines that are expected to be launched in the next 5 years including a EV71 vaccine, a pneumo conjugate vaccine, a tetravalent meningococcal conjugate vaccine, penta, MMR-Varicella and several combo vaccines.
￭ We hold 27 domestic and 4 international patents.
￭ Our newly focused area: therapeutics and diagnostics.